Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Acasti Pharma Inc
ACST
Healthcare
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the...
brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ACST)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(7)
•••
ferraridan
X
View Profile
View Bullboard History
Comment by
ferraridan
on Apr 01, 2020 4:04pm
RE:RE:RE:About time
Rosmorduc: I'm with Francine on this. Irrespective of whether they can pull this out of the fire or not they shouldn't get extra rewards. If they will be successful as you suggest
...more
(18)
•••
EternalPonzi
X
View Profile
View Bullboard History
Comment by
EternalPonzi
on Apr 01, 2020 3:25pm
RE:RE:About time
@Francine. Completely agree. Jan needs to go. Given the current climate I do not expect sp to be anywhere near a 10 banger as some on this board are predicting. Will be lucky to triple within 12
...more
GameSquare Announces Formation of FaZe Media, a Creator-led IP and Media Company, led by CEO FaZe Banks and Backed by $11 Million Investment from Matt Kalish
posted May 16, 2024 9:00am by
GameSquare Holdings Inc.
-
|
Justin Kenna, CEO of GameSquare stated, "Since completing the acquisition of FaZe Clan, we have focused on returning FaZe's founders to reboot their brand and reestablish its authenticity. We are thrilled to better capitalize this business for growth with $11 million in new capital from Matt, and to strengthen the FaZe Media board with his addition. Matt deeply believes in the power of founder and creator-led organizations and ...read more
(77)
•••
Rosmorduc
X
View Profile
View Bullboard History
Comment by
Rosmorduc
on Apr 01, 2020 3:07pm
RE:RE:About time
Francine, on the flip side, they are confident with what will happen in June or else they wouldn't doing this now. We may very well see the stock pop up 5 fold as soon as the Trilogy 2
...more
(52)
•••
Francine01
X
View Profile
View Bullboard History
Comment by
Francine01
on Apr 01, 2020 2:34pm
RE:About time
Obviously, today was the ultimate lack of respect. Here are the fact: - majority of shareholders suffered 70% - 90% losses - they screwed ph3 big time - management never bought any single
...more
(3)
•••
boozehound3
X
View Profile
View Bullboard History
Post by
boozehound3
on Apr 01, 2020 1:47pm
20 million
They have 20 million for the payroll so the game will continue
(3)
•••
boozehound3
X
View Profile
View Bullboard History
Post by
boozehound3
on Apr 01, 2020 1:45pm
About time
Wondering when they would reward themselves for the great job they did. Getting that fda meeting request in on time !!? Great job! Just think Jan is going to get paid
...more
(2)
•••
Quackers
X
View Profile
View Bullboard History
Post by
Quackers
on Apr 01, 2020 11:48am
Update
https://ca.proactiveinvestors.com/companies/news/916386/acasti-pharma-shares-nudge-higher-as-it-files-meeting-request-with-the-us-food-and-drug-administration-916386.html
(77)
•••
Rosmorduc
X
View Profile
View Bullboard History
Comment by
Rosmorduc
on Mar 30, 2020 7:52pm
RE:RE:RE:Amarin loses court battle to generics
ACST is actually up after hours. ACST wins, CAPRE will reflect its true might shortly. You wait and see. You will believe when it's all said and done. 10 bagger here.
(25)
•••
Stormdog01
X
View Profile
View Bullboard History
Comment by
Stormdog01
on Mar 30, 2020 5:38pm
RE:RE:Amarin loses court battle to generics
So far ACST down 8% after-hours. Totally agree they will most likely go and appeal. I think AMRN generic would bring some downward pressure on overall OM3 treatment market prices, but not so
...more
(52)
•••
Francine01
X
View Profile
View Bullboard History
Comment by
Francine01
on Mar 30, 2020 5:23pm
RE:Amarin loses court battle to generics
Still dont know if good or bad news for Acasti, they were not in the cv market and could now produce generic of Amarin and claim cv benefits !? I think I could be good news, because OM3 market will
...more
(0)
•••
smb160572
X
View Profile
View Bullboard History
Post by
smb160572
on Mar 30, 2020 5:18pm
CRASH BANG WALLOP AMARIN
Feel the pain Amarin. You b'st##s have been bashing Acasti for months. Oh dear....lol
(25)
•••
Stormdog01
X
View Profile
View Bullboard History
Post by
Stormdog01
on Mar 30, 2020 5:15pm
Amarin loses court battle to generics
https://seekingalpha.com/news/3556531-amarin-plunges-after-court-decision-on-vascepa?utm_source=dashboard.stck.pro&utm_medium=referral
(77)
•••
Rosmorduc
X
View Profile
View Bullboard History
Comment by
Rosmorduc
on Mar 30, 2020 1:11pm
RE:Read AMarin s latest
Yah and placebo cornstarch gave better results than Amarin's product.
(52)
•••
Francine01
X
View Profile
View Bullboard History
Comment by
Francine01
on Mar 30, 2020 12:34pm
RE:Read AMarin s latest
Boose, you are still confusing CV (Amarin) and diabetics angle (Acasti) with the 2/3 phospholipids composition, which was always different from Vascepa (pure EPA) and Epanova (EPA/DHA with no
...more
(3)
•••
boozehound3
X
View Profile
View Bullboard History
Post by
boozehound3
on Mar 30, 2020 12:10pm
Read AMarin s latest
Once again saying. EPA is the way. The rest doesn't work. I think it's over for capre
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment
IAMGOLD Reports First Quarter 2024 Results
Xcyte Digital Corp. Releases "Xperience" Subscription Service
Drilling Approval Received for New Mexico Lithium Project
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition